

Coronavirus update

February 18, 2020

- Cardinal Health takes its responsibility to maintain service to our customers during crisis situations very seriously, as demonstrated through our history of service during natural and human-made events. We take a holistic approach to emergency preparedness and are committed to the continuity of service in the event of a crisis.
- The 2019 Novel Coronavirus (COVID-19) is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China and continues to spread across China and other countries. Cardinal Health has implemented pre-established business continuity and pandemic contingency plans, working in accordance with guidelines set by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and Human Services (HHS).
- Given the potential impact of extended company shutdowns on the global pharmaceutical supply chain, our partners at Red Oak Sourcing have proactively reached out to our suppliers to understand any potential impact of the coronavirus on future product supply.
- While relatively few finished-dose products are produced in China, some active pharmaceutical ingredients (API) and certain other raw materials are produced in various parts of China
- Similarly, Red Oak Sourcing reached out to our largest suppliers to confirm the potential impact on product availability
 - Initial supplier feedback is as follows:
 - Many of our suppliers have confirmed they hold several months' worth of API safety stock.
- At this point, we are not aware of any Chinese port closings that may impact raw material availability.
- While we do not anticipate any current impact to product availability, Cardinal Health and Red Oak Sourcing continue to actively monitor the situation as it develops and remain in close contact with our supplier partners.